Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
  • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
  • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

• the present invention relates to an aqueous gel as well as its use. More particularly the present invention relates to an aqueous gel showing transparency, lubricity, stringiness, elongation, extensiveness and cohesiveness while being devoid of taste and smell and not being tacky.
• the aqueous gel according to the invention may be used as a lubricant, e.g. as carrier for active ingredients such as local anaesthetics, analgesics and other API's and as a carrier for excipients, as a saliva replacement or food lubricant, and as a lubricant on mucosal surfaces, serosal surfaces and skin. Other uses may be submucosal application either for endoscopic mucosal lifting or for carrier of excipients.
• Hydrophilic polymers are well known in the art as rheology modifiers of aqueous systems. For instance, they are used as thickeners for a wide range of functional systems such as cosmetics, personal care products and medicine.
• Artificial saliva or saliva substitutes can be used to replace moisture and lubricate in the oral cavity and thereby alleviate oral dryness. These substitutes are available commercially, but they can also be compounded. Artificial salivas are formulated to mimic natural saliva. However, they are often proven to be ineffective for most patients suffering from persistent salivary gland hypofunction and xerostomia (i.e., sensation of dry mouth).
• Saliva is important for the maintenance of oral health, and also plays an essential role in a number of oral and gastrointestinal functions. Consequently, patients with reduced salivary secretion and changes in their saliva composition are more susceptible to dental caries, oral infections and mucosal lesions, and often have symptoms of a dry and sore mouth, burning and itching oral mucosa, difficulties in chewing and swallowing dry foods, impaired sense of taste, difficulty in speaking, and problems with acid reflux. These distressing consequences of salivary hypofunction also have a significant negative impact on quality of life and general health status. Several diseases and medical conditions as well as the medications used for treating them, are associated with salivary gland hypofunction (objective evidence of diminished salivary output) and xerostomia (subjective sensation of dry mouth). In autoimmune diseases like Sjögren's syndrome, salivary gland dysfunction is largely related to structural changes in the salivary glands.
• Different spray formulations are available, which are meant to be applied directly to the mouth and throat of a patient suffering from salivary gland hypofunction before swallowing a food item.
• the patient liquefies the food in a blender or food processor.
• U.S. Pat. No. 4,740,365 discloses a sustained-release preparation used for mucous membranes in the oral cavity.
• U.S. Pat. No. 5,068,225 relates to a viscoelastic fluid for use in surgery and other therapies and method of using same.
• U.S. Pat. No. 6,133,325 relates to bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions.
• U.S. Pat. No. 8,823,334 relates to a topical anesthetic containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the mucosa.
• WO 92/03124 discloses a polymeric complex composition comprising a reaction complex formed from a polycarbophil and alginic acid.
• WO 92/09256 relates to a water-based human tissue lubricant.
• WO 02/087519 relates to shaving compositions containing highly lubricious water soluble polymers.
• US 2005/0226822 relates to oral care products containing ovomucin.
• US2005/0244521 discloses a tobacco composition comprising tobacco and a “format”, wherein said composition is readily disintegrable in the mouth, and wherein said format may comprise a polymer.
• WO 2006/028578 discloses use of polyethylene glycol based fluidized polymer suspension in functional systems.
• WO 2006/124219 discloses a shaving composition comprising water, a water dispersible surface active agent, a lubricious water soluble polymer, water insoluble particles, and a hydrogel-forming polymer.
• EP 0 613 684 relates to a solid form product for alleviating xerostomia.
• active ingredients to the oral cavity and throat such as local anaesthetics, analgesics, anti-inflammatory agents, anti-infective agents such as antifungal, antibacterial, antiviral and anti-parasitic agents, caries preventive agents, and optionally, pH regulating agents, flavouring agents, taste correcting substances, texture modifiers, colourants and preservatives.
• aqueous gel composition comprising:
• aqueous gel composition comprising:
• aqueous gel composition comprising:
• the present invention relates to an aqueous gel composition
• an aqueous gel composition comprising water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is above 98% by weight of the composition, more preferably in the range 98.5-99.5% by weight of the composition, such as in the range 98.7-99.3% by weight of the composition.
• the present invention relates to an aqueous gel composition according to the invention for use as a lubricant for mucosal membranes, serosal surfaces, skin and for submucosal applications.
• the present invention relates to an aqueous gel composition according to the invention for use as a lubricant for devices and appliances.
• aqueous gel refers to an aqueous dispersion comprising water and a hydrophilic polymeric substance dispersed therein.
• additive refers to any active ingredient for use in an aqueous gel composition according to the invention.
• Non-limiting examples thereof include local anaesthetics, analgesics, anti-inflammatory agents, anti-infective agents such as antifungal, antibacterial, antiviral and anti-parasitic drugs, anti-caries agents or caries-preventive agents, and excipients such as pH regulating agents, preservatives, texture modifiers, colourants, flavouring agents and taste correcting substances.
• polysaccharide refers to a polymeric carbohydrate molecule composed of long chains of monosaccharide units bound together by glycosidic linkages.
• cellulose refers to an organic compound with the general formula (C 6 H 10 O 5 ) n , a polysaccharide consisting of a linear chain of several hundred to over ten thousand ⁇ (1->4) linked D-glucose units.
• a “derivative” of cellulose refers to a cellulose compound, wherein the hydroxyl groups thereof are partially or fully reacted with various substituents.
• polyethylene oxide PEO
• polyoxyethylene POE
• PEG polyethylene glycol
• saliva substitute refers to a substance used to substitute the saliva in patients having a dry mouth or xerostomia.
• food lubricant refers to a preparation which, when added to food prior to insertion into the mouth will, upon mastication enable the formation of an easily swallowable bolus.
• lubricancy and “lubricity”, which in the present context are used interchangeably, refers to the property of a composition to lubricate, i.e. make slippery, smooth and lessen friction.
• the water content of the aqueous gel composition is at least 95% by weight of the composition, more preferably at least 97% by weight of the composition.
• the water content is above 98% by weight of the composition, more preferably in the range 98.5-99.5% by weight of the composition, such as in the range 98.7-99.3% by weight of the composition.
• the at least one polysaccharide is selected from the group consisting of cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin, carrageenan and alginates.
• the at least one cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin and carrageenan is selected from the group consisting of methylcellulose, carboxy-methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, tara gum, guar gum, arabic (Acacia) gum, gellan gum, pullulan gum, cassia gum, carob gum, carregeenan, pectin, locust bean gum, welan gum, konjac, and karaya.
• the methylcellulose, carboxy-methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, tara gum, guar gum, arabic (Acacia) gum, gellan gum, pullulan gum, cassia gum, carob gum, carregeenan, pectin, locust bean gum, welan gum, konjac, and karaya is preferably selected from the group consisting of methylcellulose, carboxy-methylcellulose, hydroxypropylmethylcellulose, xanthan gum, and guar gum, more preferably methylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, gellan gum or xanthan gum.
• the above polysaccharides are devoid of any taste and smell and are available at low cost.
• the at least one polysaccharide is a methylcellulose or a hydroxypropylmethyl cellulose and is preferably hydroxypropylmethyl cellulose (HPMC).
• HPMC hydroxypropylmethyl cellulose
• Methylcellulose and hydroxypropyl methylcellulose are available commercially under the trade name METHOCELTM as a line of cellulose ether products produced by The Dow Chemical Company.
• the initial letter identifies the type of cellulose ether.
• An “A” identifies methylcellulose products and “E”, “F”, “K”, “J” and “310-series” identify different hydroxypropyl methylcelluloses.
• the at least one high molecular weight polyethylene oxide is of a molecular weight of at least 200,000, preferably of a molecular weight of at least 600,000, preferably of a molecular weight of at least 1,000,000, such as in the range 1,000,000 to 7,000,000, more preferably of a molecular weight in the range 1,000,000-6,000,000, such as of a molecular weight in the range 1,000,000 to 5,000,000, such as of a molecular weight in the range 1,000,000 to 4,000,000.
• Polyethylene oxide polymers are available commercially under the trade name of POLYOXTM followed by a subscript indicating its type. Thus e.g. POLYOXTM 301 refers to a PEO having a molecular weight of approximately 4,000,000, whereas POLYOXTM 303 refers to a PEO having a molecular weight of approximately 7,000,000.
• the content of the at least one polysaccharide is in the range 0.1-3% by weight of the composition, more preferably in the range 0.3-2.0% by weight of the composition, such as in the range 0.4-1.5% by weight of the composition, more preferably in the range 0.5-1.5% by weight of the composition, such as about 0.6-1.2% by weight of the composition, such as about 0.8% by weight of the composition.
• the content of the at least one high molecular weight polyethylene oxide is in the range 0.05-2% by weight of the composition, more preferably in the range 0.1-1% by weight of the composition, more preferably in the range 0.1-0.5% by weight of the composition, such as about 0.3% by weight of the composition.
• the content of the at least one polysaccharide in the composition is in the range 0.5-1.5% by weight of the composition, preferably in the range 0.6-1.2% by weight of the composition, such as about 0.8% by weight of the composition, and the content of the at least one high molecular weight polyethylene oxide in the composition is in the range 0.1-1% by weight of the composition, preferably in the range 0.1-0.5% by weight of the composition, such as about 0.3% by weight of the composition.
• the aqueous gel composition according to the invention comprises a local anaesthetic agent or analgesic agent selected from procaine, amethocaine, cocaine, lidocaine (also known as Lignocaine), prilocaine, bupivacaine, levobupivacaine, ropivacaine, mepivacaine, dibucaine, benzocaine, tetracaine, etidiocine, and ropivacaine. It is to be understood, however, that the above list is non-exhaustive and that other local anaesthetic agents or analgesic agents may be used in a particular aqueous gel composition according to the invention.
• the aqueous gel composition further comprises at least one additive.
• additives selected from the group consisting of a flavouring agent, a taste correcting substance, a texture modifier (such as one or more lipids), a colourant, a pH regulating agent, a preservative, a therapeutically active agent, such as sucralfate, a steroid, a caries-preventive agent (such as e.g. fluoride), an antifungal agent, an antibacterial agent (such as e.g. Lyzozyme, triclosan, metronidazole), an antiviral agent (acyclovir), and an anti-parasitic agent.
• the aqueous gel composition according to the invention may be prepared in a manner known per se.
• non-limiting examples of the preparation thereof may be found in Handbook of Pharmaceutical Excipients, fifth ed., Raymond C Rowe et al. and include mixing of the polymers with ice-cold water under vigorous agitation; wetting the polymers with a portion of hot, 65-85° C., water and then adding, under agitation, the rest of the water as ice or ice-water; or the polymers may be moistened with an organic solvent such as ethanol prior to the addition of water.
• the aqueous gel composition comprises an active ingredient for the treatment of oral mucosal conditions/diseases such as lichen planus, candidiasis, angular cheilitis, recurrent aphthous stomatitis, recurrent herpes labialis, glossitis/stomatitis migrans, discoid lupus lesions, burning mouth syndrome, burning mouth syndrome, mucositis a.o.
• oral mucosal conditions/diseases such as lichen planus, candidiasis, angular cheilitis, recurrent aphthous stomatitis, recurrent herpes labialis, glossitis/stomatitis migrans, discoid lupus lesions, burning mouth syndrome, burning mouth syndrome, mucositis a.o.
• it might be used as eye lubricant and as carrier of active substances to the eyes.
• it may be used as lubricant in massage and sexual activities.
• it might be used as a carrier of active substances to the vagina, urethra, uterus, nose, sinus, throat, ears, or rectum or any other mucosal or serosal tissue or skin.
• a number of aqueous gel compositions were prepared by adding the pre-weighted and premixed polymers to the water at low temperature (under 3° C.) while agitating the water with an Electrolux Stick Mixer ESTM 6200 at highest speed. The agitation was maintained until no more dry particles or lumps could be seen.
• An aqueous vehicle having the following composition:
• HPMC Metal K250M
• sucralfate-containing gel composition was prepared by adding the polyethylene oxide and HPMC to ice-cold water while agitating the mixture with an Electrolux Stick Mixer ESTM 6200 at highest speed. The agitation was maintained until no more dry particles or lumps could be seen. Sucralfate in an amount of 5.3% by weight of the above vehicle was added under stirring to obtain a sucralfate-containing gel composition.
• sucralfate-containing gel composition was administered to patients with xerostomia also having inflammatory mucosal lesions twice daily at a dose of one spoonful per dose. Significant symptom relief was observed after a few days of treatment.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pain & Pain Management (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Reproductive Health (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Urology & Nephrology (AREA)
• Gynecology & Obstetrics (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=50774669

Family Applications (2)

Family Applications After (1)

Country Status (8)

Cited By (1)

Families Citing this family (2)

Family Cites Families (12)

• 2015
  • 2015-05-21 EP EP15727329.3A patent/EP3145548B1/en active Active
  • 2015-05-21 WO PCT/EP2015/061282 patent/WO2015177288A1/en not_active Ceased
  • 2015-05-21 ES ES15727329T patent/ES2916210T3/es active Active
  • 2015-05-21 AU AU2015261841A patent/AU2015261841B2/en active Active
  • 2015-05-21 DK DK15727329.3T patent/DK3145548T3/da active
  • 2015-05-21 US US15/312,960 patent/US20170189333A1/en not_active Abandoned
  • 2015-05-21 CA CA2949304A patent/CA2949304C/en active Active
  • 2015-05-21 PL PL15727329.3T patent/PL3145548T3/pl unknown
• 2021
  • 2021-01-13 US US17/147,957 patent/US11793752B2/en active Active

Also Published As

Similar Documents

Legal Events